Delving into the Latest Updates on SMF-210 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

SMF-210

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertension

Inactive Indication-

Originator Organization

Jiangxi Shimei Pharmaceutical Co., Ltd.

Active Organization

Jiangxi Shimei Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseClinical

First Approval Date-

Regulation-

Login to view timeline

主要研究目的：研究空腹/餐后状态下口服受试制剂与参比制剂在中国健康成年参与者体内的药代动力学特征，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂和参比制剂在中国健康成年参与者中的安全性。

[Translation]

Primary study objectives: To investigate the pharmacokinetic characteristics of the test and reference formulations in healthy Chinese adults after oral administration in the fasting and fed states, and to evaluate the bioequivalence of the two formulations after oral administration in the fasting and fed states. Secondary study objectives: To evaluate the safety of the test and reference formulations in healthy Chinese adults.

Start Date-

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

100 Clinical Results associated with SMF-210

Login to view more data

100 Translational Medicine associated with SMF-210

Login to view more data

100 Patents (Medical) associated with SMF-210

Login to view more data

100 Deals associated with SMF-210

Login to view more data